Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.53
13.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Joincare Pharmaceutical Group Industry Co Ltd
Other Liabilities
Joincare Pharmaceutical Group Industry Co Ltd
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380
|
Other Liabilities
¥444m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
9%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Liabilities
¥22m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Liabilities
¥94.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Liabilities
¥42.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Liabilities
¥892.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
17%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Liabilities
¥26.8m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Joincare Pharmaceutical Group Industry Co Ltd
Glance View
Joincare Pharmaceutical Group Industry Co. Ltd., a noteworthy player in China's bustling pharmaceutical landscape, emerged as a beacon of innovation and resilience. With its roots stretching back to the mid-1990s, the company has consistently carved out a substantial niche in both the generic and proprietary drug markets. Its ability to synergistically blend cutting-edge research with cost-efficient production has been instrumental in ensuring its position as a formidable competitor. Joincare harnesses a robust pipeline of drugs targeting prevalent chronic diseases, complemented by its investment in high-growth biopharmaceuticals. From research and development to manufacturing and distribution, Joincare manages an integrated pharmaceutical supply chain that not only propels its profitability but also reinforces its mission to enhance public health. The company thrives on a diverse revenue model by leveraging both its proprietary products and a broad array of generic pharmaceuticals. It capitalizes on sustained demand for its products across domestic and international markets, ensuring a steady stream of income. By focusing on quality and affordability, Joincare has successfully navigated the complex regulatory landscape, earning certifications that open doors to global markets. This strategic emphasis on rigorous compliance not only mitigates risks but also builds trust with healthcare professionals and end-users alike. Through these efforts, Joincare continues to fortify its market position, all while contributing to the ever-evolving pharmaceutical industry with a pioneering spirit and an unwavering commitment to improving healthcare accessibility.
See Also
What is Joincare Pharmaceutical Group Industry Co Ltd's Other Liabilities?
Other Liabilities
444m
CNY
Based on the financial report for Sep 30, 2024, Joincare Pharmaceutical Group Industry Co Ltd's Other Liabilities amounts to 444m CNY.
What is Joincare Pharmaceutical Group Industry Co Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
9%
Over the last year, the Other Liabilities growth was -12%. The average annual Other Liabilities growth rates for Joincare Pharmaceutical Group Industry Co Ltd have been -6% over the past three years , 1% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
